INCY vs INDV
Incyte vs Indivior Pharmaceuticals Inc — AI-powered side-by-side comparison
VS
INDV
Indivior Pharmaceuticals Inc
58
Watch
| Metric | INCY | INDV |
|---|
| AI Score |
72
|
58
|
| Price |
$121.08
|
$38.42
|
| P/E Ratio |
14.89×
|
13.53×
|
| ROE |
24.9%
|
-214.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
83.9%
|
| Debt / Equity |
0.01×
|
-2.45×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
42.6
|
| Beta |
0.769
|
1.0251
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus INDV.
INCY leads by 14 points.
INCY scores 72/100 (Buy) versus INDV at 58/100 (Watch).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
INDV Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical